Asha Therapeutics Launches Zero-Shot Drug Design Company

New AI-powered startup Atom Therapeutics aims to revolutionize drug discovery.

Mar. 30, 2026 at 6:08pm

Got story updates? Submit your updates here. ›

An abstract, highly structured painting featuring sweeping geometric arcs, concentric circles, and precise botanical spirals in a vibrant color palette of blues, greens, and purples against a clean white background, conceptually representing the complex computational processes and molecular structures involved in Atom Therapeutics' innovative drug discovery technology.Atom Therapeutics' revolutionary zero-shot drug design platform harnesses the power of AI to rapidly generate and validate innovative new therapeutic compounds.Today in Tampa

Asha Therapeutics, a new biotech startup based in Tampa, Florida, has launched Atom Therapeutics, the first company to use zero-shot de novo drug design powered by artificial intelligence. Atom Therapeutics is pioneering a novel approach to molecular drug discovery that aims to dramatically accelerate the development of new therapeutic compounds.

Why it matters

Atom Therapeutics' zero-shot drug design technology could disrupt the traditional pharmaceutical R&D model, which is often slow, expensive, and prone to failure. By leveraging AI to design new drug candidates from scratch, the company hopes to bring innovative treatments to market faster and more efficiently.

The details

Atom Therapeutics is using advanced machine learning algorithms and computational chemistry to generate novel drug molecules without the need for physical experimentation or testing. The company's proprietary technology allows it to rapidly explore vast chemical spaces and identify promising drug candidates that can then be validated and optimized through further development.

  • Asha Therapeutics launched Atom Therapeutics in March 2026.

The players

Asha Therapeutics

A new biotech startup based in Tampa, Florida that has launched Atom Therapeutics, the first company to use zero-shot de novo drug design powered by artificial intelligence.

Atom Therapeutics

A subsidiary of Asha Therapeutics that is pioneering a novel approach to molecular drug discovery using advanced AI and computational chemistry to rapidly generate and validate new drug candidates.

Got photos? Submit your photos here. ›

What’s next

Atom Therapeutics plans to use its zero-shot drug design platform to rapidly develop a pipeline of novel therapeutic candidates across a range of disease areas, with the goal of bringing its first drug to clinical trials within the next 3-5 years.

The takeaway

Atom Therapeutics' AI-powered approach to drug discovery has the potential to dramatically accelerate the development of new medicines, potentially reducing the time and cost associated with traditional pharmaceutical R&D.